CA
NZ
UK
AU
IND
US
…
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Upstream Bio, Inc. (NASDAQ: UPB) is a publicly traded biotechnology company that, per corporate disclosures, focuses on developing novel therapeutics. Its long-term growth drivers appear to be clinical progress, partnerships, and potential regulatory approvals, which may appeal to investors seeking pipeline upside.
Principal risks are clinical and regulatory setbacks, high cash burn and financing needs, and sparse public information that reduces visibility into programs and timelines.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Income before tax | -143.44M | -62.81M | -20.54M | -23.87M |
| Net income | -143.44M | -62.81M | -20.54M | -23.87M |
| Selling general administrative | 26.41M | 17.17M | 10.70M | 6.46M |
| Gross profit | 2.85M | 2.37M | 2.38M | 1.21M |
| Reconciled depreciation | 0.19M | 0.09M | 0.06M | 0.01M |
| Ebit | -143.44M | -62.81M | -20.54M | -23.87M |
| Ebitda | -143.25M | -62.72M | -20.48M | -23.86M |
| Depreciation and amortization | 0.19M | 0.09M | 0.06M | 0.01M |
| Operating income | -160.36M | -77.76M | -40.11M | -23.91M |
| Other operating expenses | 163.22M | 80.13M | 42.49M | 25.12M |
| Interest income | 16.93M | 12.12M | 4.17M | 0.20M |
| Net interest income | 16.93M | 12.12M | 4.17M | 0.20M |
| Total revenue | 2.85M | 2.37M | 2.38M | 1.21M |
| Total operating expenses | 163.22M | 80.13M | 42.49M | 25.12M |
| Cost of revenue | 0.19M | 0.09M | 0.06M | 0.01M |
| Total other income expense net | 16.92M | 14.96M | 19.58M | 0.04M |
| Net income from continuing ops | -143.44M | -62.81M | -20.54M | -23.87M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Total assets | 353.77M | 481.72M | 117.20M | 18.48M |
| Other current assets | 9.62M | 7.53M | 6.95M | 0.84M |
| Total liab | 14.00M | 11.87M | 240.32M | 124.63M |
| Total stockholder equity | 339.77M | 469.85M | -123.13M | -106.16M |
| Other current liab | 10.01M | 5.99M | 4.48M | 4.06M |
| Common stock | 0.05M | 0.05M | 0.00M | 0.00M |
| Capital stock | 0.05M | 0.05M | 0.00M | 0.00M |
| Retained earnings | -334.22M | -190.78M | -127.97M | -107.44M |
| Cash | 101.58M | 325.89M | 25.83M | 17.05M |
| Total current liabilities | 13.45M | 10.74M | 6.51M | 4.86M |
| Net debt | -100.31M | -324.06M | -25.79M | -16.96M |
| Short term debt | 0.72M | 0.70M | 0.04M | 0.09M |
| Short long term debt total | 1.27M | 1.83M | 0.04M | 0.09M |
| Other stockholder equity | 673.41M | 660.60M | 4.82M | 1.28M |
| Total current assets | 351.80M | 479.16M | 117.00M | 18.31M |
| Short term investments | 239.93M | 144.56M | 83.98M | 0.00M |
| Net receivables | 0.67M | 1.18M | 0.24M | 0.41M |
| Accounts payable | 2.73M | 4.04M | 1.99M | 0.71M |
| Accumulated other comprehensive income | 0.53M | -0.03M | 0.02M | - |
| Non currrent assets other | 0.19M | 0.19M | -0.00M | 0.01M |
| Non current assets total | 1.98M | 2.56M | 0.20M | 0.17M |
| Capital lease obligations | 1.27M | 1.83M | 0.04M | 0.09M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Investments | -93.31M | -59.48M | -82.84M | -0.08M |
| Total cashflows from investing activities | -93.48M | -59.48M | -82.84M | -0.08M |
| Total cash from financing activities | 2.44M | 418.91M | 129.55M | 9.96M |
| Net income | -143.44M | -62.81M | -20.54M | -23.87M |
| Change in cash | -224.31M | 300.25M | 8.78M | -9.14M |
| Begin period cash flow | 326.09M | 25.83M | 17.05M | 26.19M |
| End period cash flow | 101.77M | 326.09M | 25.83M | 17.05M |
| Total cash from operating activities | -133.28M | -59.17M | -37.93M | -19.02M |
| Issuance of capital stock | 0.00M | 422.65M | 129.43M | 10.00M |
| Depreciation | -1.31M | 0.09M | 0.06M | 0.01M |
| Change to account receivables | -0.06M | -0.52M | 0.31M | -0.41M |
| Other cashflows from financing activities | - | 146.19M | 129.43M | 9.96M |
| Capital expenditures | 0.17M | 0.51M | 0.14M | 0.08M |
| Change in working capital | 0.59M | 1.87M | -4.30M | 3.41M |
| Stock based compensation | 10.33M | 6.00M | 3.43M | 1.28M |
| Other non cash items | 0.56M | -4.33M | -16.57M | 0.15M |
| Free cash flow | -133.28M | -59.68M | -38.07M | -19.10M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| UPB Upstream Bio, Inc. |
0.02 0.62% |
3.23 | - | - | 95.04 | 1.17 | 18.32 |
| NVO Novo Nordisk A/S |
0.01 0.02% |
40.31 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 |
| VRTX Vertex Pharmaceuticals Inc |
4.59 0.85% |
547.09 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 |
| REGN Regeneron Pharmaceuticals Inc |
1.45 0.16% |
904.35 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 |
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. E. Rand Sutherland M.D., M.P.H. | CEO & Director | 1970 |
| Mr. Michael Paul Gray CPA, MBA | CFO & COO | 1971 |
| Mr. Aaron Deykin M.D. | Chief Medical Officer and Head of Research & Development | 1967 |
| Ms. Stacy Price M.S., P.M.P. | Chief Technology Officer | 1969 |
| Meggan Buckwell | Director of Corporate Communications & Investor Relations | NA |
| Ms. Allison C. Ambrose J.D. | Senior VP, General Counsel & Secretary | 1985 |
| Ms. Lisa Fiering | Senior Vice President of People & Culture | NA |
| Dr. Adam Houghton M.B.A., Ph.D. | Chief Business Officer | 1971 |
| Ms. Mersedeh Miraliakbari Pharm.D. | Senior Vice President of Regulatory Affairs & Quality | NA |
| Ms. Fang Xie Ph.D. | VP & Head of Biometrics | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...